Ticagrelor more cardioprotective than clopidogrel
NEW YORK (Reuters Health) - Ticagrelor is better than clopidogrel at reducing cardiovascular events -
including recurrent events - in patients with acute coronary syndromes, researchers say. (Source: Modern Medicine)
Source: Modern Medicine - January 11, 2013 Category: Journals (General) Source Type: news
Cangrelor at PCI Cuts Ischemic Events vs ClopidogrelCangrelor at PCI Cuts Ischemic Events vs Clopidogrel
Not yet approved by regulators anywhere, the novel P2Y12-receptor antagonist reduced the risk of 48-hour ischemic events compared with the older antiplatelet. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 8, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Early Results: Antiplatelet Drug Cangrelor Superior to Clopidogrel In PCI Patients At 48 Hours
The experimental antiplatelet drug cangrelor was superior to traditional clopidogrel in reducing ischemic events at 48 hours in PCI patients, according to the Medicines Company, which is developing the drug. The company today announced positive results from the phase 3 CHAMPION PHOENIX trial, a randomized, double-blind study comparing intravenous cangrelor to oral clopidogrel in PCI patients. The primary endpoint was the composite of death, MI, revascularization and stent thrombosis at 48 hours. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 8, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
Cangrelor at PCI cuts ischemic events vs clopidogrel: Preliminary phase 3 results
Not yet approved by regulators anywhere, the novel P2Y12-receptor antagonist reduced the risk of 48-hour ischemic events compared with the older antiplatelet. (Source: theHeart.org)
Source: theHeart.org - January 8, 2013 Category: Cardiology Source Type: news
Prasugrel after clopidogrel safe in acute coronary syndrome: study
NEW YORK (Reuters Health) - Prasugrel reloading after clopidogrel loading appears safe before
percutaneous interventions for acute coronary syndrome (ACS), a new paper says. (Source: Modern Medicine)
Source: Modern Medicine - January 8, 2013 Category: Journals (General) Source Type: news
Fibrinogen Level Tied to Poorer PCI Outcomes (CME/CE)
(MedPage Today) -- An elevated serum fibrinogen level predicted worse short-term ischemic outcomes among patients undergoing elective percutaneous coronary intervention after pretreatment with clopidogrel, researchers found. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 7, 2013 Category: Cardiology Source Type: news
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomised evaluation of long-term anticoagulation therapy (RE-LY®) trial: subgroup analysis
Source: Circulation
Area: News
RE-LY showed that dabigatran etexilate 150 mg bid (DE150) was superior, and 110 mg bid (DE110) non-inferior to warfarin in preventing stroke and systemic embolism (SSE) in patients with atrial fibrillation (AF). A common clinical dilemma regarding treatment of patients with AF is the need to use concomitant antiplatelets for a variety of reasons. While the combination of OAC and antiplatelets carry the potential of additive benefits, they also carry the danger of increased risk of bleeding.
With the emergence of dabigatran, questions on its efficacy and safety in patients receivi...
Source: NeLM - Cardiovascular Medicine - January 4, 2013 Category: Cardiology Source Type: news
Reduced copayment policy has benefits all round
Reducing patients’ copayments for statins and clopidogrel could increase their adherence without adding financial burden to the healthcare system, researchers say. (Source: MedWire News - Thrombosis)
Source: MedWire News - Thrombosis - October 18, 2012 Category: Internal Medicine Source Type: news
Cardiovascular Patients With a Certain Gene Mutation Respond Better to Higher Clopidogrel Doses
Current standard dosage for Clopidogrel may not be effective for individuals with a certain gene mutation that prevents the body from converting the medicine to a form it can use. (Source: BWH News)
Source: BWH News - November 16, 2011 Category: Hospital Management Source Type: news
